Call Us: +1 (650) 364-7016

The Company, based in Menlo Park, CA, has developed a novel transcatheter implant called the Parachute™ Ventricular Partitioning Device (Parachute™). The Parachute™ intends to treat heart failure resulting from a heart attack in patients worldwide by improving overall cardiac function.
Maria Sainz Joins CardioKinetix
Brings Proven Record of Success in Commercializing Innovative Therapies
Menlo Park, Calif – CardioKinetix Inc, a
CardioKinetix Announces Late Breaking
Two-Year Data on Breakthrough Treatment to be Presented on Friday, May 18
Menlo Park, Calif —
CardioKinetix Wins Edison Award
Awards Honor Innovation, Creativity and Ingenuity
Menlo Park, CA – CardioKinetix Inc, a pioneer in catheter-based treatments for
“We continue to be encouraged by the early clinical results demonstrated by the ParachuteTM implant. In all of our previous studies we have seen similar improvements in treated heart failure patients.”
Thomas Engels, Vice President of Clinical Affairs of CardioKinetix Inc.